Synergistic interactions between fenfluramine and phentermine

International Journal of Obesity

Volumn 23, Issue 7, 1999, Pages 723-732

  Wellman, P J ^a   Maher, T J ^b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Drug drug interactions; Isobologram; Monoamine oxidase inhibitors; Serotonin

Indexed keywords

ANOREXIGENIC AGENT; FENFLURAMINE; PHENTERMINE; SEROTONIN;

APPETITE; ARTICLE; BODY WEIGHT; DRUG DISTRIBUTION; DRUG POTENTIATION; HUMAN; LUNG VASOCONSTRICTION; PRIORITY JOURNAL; SATIETY; SEROTONIN BRAIN LEVEL; VALVULAR HEART DISEASE;

EID: 0032994575     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0800920     Document Type: Article

References (65)

1. 1 Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994; 272: 205-211.
2. 2 Bray GA. Health hazards of obesity. Endocrinol Metabol Clin N Am 1996; 25: 907-919.
3. 3 Pingitore R, Dugoni BL, Tindale RS, Spring B. Bias against overweight job applicants in a simulated employment interview. J Appl Psychol 1994; 79: 909-917.
4. 4 Blackburn GL, Miller D, Chan S. Pharmaceutical treatment of obesity. Nursing Clin of N Am 1997; 32: 831-848.
5. 5 Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Int Med 1993; 119/7:Pt 2: 1-13.
6. 6 Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Internal Med 1984; 144: 1143-1148.
7. 7 Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Therap 1994; 51: 642-646.
8. 8 Kassirer JP, Angell M. Losing weight - An ill-fated new years resolution. New Eng J Med 1998; 338: 52-54.
9. 9 Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. New Eng J Med 1977; 337: 581-588.
10. 10 Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. New Eng J Med 1996; 335/9: 609-616.
11. 11 Brenot F, Herve P, Petipretz P, Paren F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Brit Hrt J 1993; 70: 537-541.
12. 12 Delcroix M, Kurz X, Walckiers D, Demedts M, Nacije R. High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium. Eur Respir J 1998; 12: 271-276.
13. 13 Follath F, Burkart F, Schweize, W. Drug-induced pulmonary hypertension? BMJ 1971; 1/5743: 265-266.
14. 14 Mark EJ, Patalas ED, Chang HT, Evans RJ, Kessler SC. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. New Eng J Med 1997; 337: 602-606.
15. 15 Simonneau G, Fartoukh M, Sitbon O, Humbert M, Jagot JL, Herve P. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998; 114/3: Suppl, S195-S199.
16. 16 Rea WP, Rothman RB, Shippenberg TS. Evaluation of the conditioned reinforcing effects of phentermine and fenfluramine in the rat - concordance with clinical studies. Synapse 1998; 30: 107-111.
17. 17 Blundell JE. Is there a role for serotonin (5-hydroxytryptamine) in feeding? In J Obes 1977; 1: 15-42.
18. 18 Garattini S. Biological actions of drugs affecting serotonin and eating. Obesity Res 1995; 3: (Suppl): S470.
19. 19 Garattini S, Bizzi A, Caccia S, Mennini T, Samanin R. Progress in assessing the role of serotonin in the control of food intake. Clin Neuropharmacol 1988; 11: Suppl, S32.
20. 20 Heal DJ, Cheetam SC, Prow MR, Martin KF, Buckett WR. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight modifying agents. Br. J. Pharmacol 1998; 125: 301-308.
21. 21 Gundlach C, Martin KF, Heal DJ, Auerbach SB. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: Sibutramine is a reuptake inhibitor. J Pharmacol Exp Therap 1997; 283: 581-591.
22. 22 Curzon G, Gibson EL, Oluyomi AO. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci 1977; 18: 21-25.
23. 23 Bray GA. Evaluation of drugs for treating obesity. Obesity Res 1995; 3: Suppl, S434.
24. 24 Yelnosky J, Panasevich RE, Borrelli AR, Lawlor RB. Pharmacology of phentermine. Archives Internationales de Pharmacodynamie et de Therape 1969; 178: 62-76.
25. 25 Roth JD, Rowland NE. Efficacy of administration of dexfenfluramine and phentermine, alone and in combination, on ingestive behavior and body weight in rats. Psychopharmacol 1998; 137: 99-106.
26. 26 Roth JD, Rowland NE. Anorectic efficacy of the fenfluramine/phentermine combination in rats: additivity or synergy? Eur J Pharmacol 1999; in press.
27. 27 Wellman PJ, Tow S, McMahon L. Isobolographic assessment of the effects of combinations of phenylpropanolamine and fenfluramine on food intake in rats. Pharmacol Biochem Behav 1995; 50: 287-291.
28. 28 Gurtner HP, Aminorex and pulmonary hypertension. A review. Cor et Vasa 1985; 27: 160-171.
29. 29 Douglas JG, Munro JF, Kitchin AH, Muir AL, Proudfoot AT. Pulmonary hypertension and fenfluramine. Br Med J 1981; 6296: 881-883.
30. 30 Backmann R, Dengler H, K Gahl, Greiser R, Jesdinsky HJ, Loogen F. Primary Pulmonary Hypertension. Darmstadt: Dr. Dietrich Steinkopff Publishers, 1972.
31. 31 Heuer L, Benoit W, Hoydrich H, Kummer D, Schick J. Pulmonale hypertonie durch appetitzughr (Mirapront). Chir Praxix 1978; 23: 497-504 (German).
32. 32 Schnabel KH, Shatz V, Busch S, Just H. Drug-induced primary vascular pulmonary hypertension. Med Welt 1976; 27: 1300-1303.
33. 33 Fishman AP. Aminorex to Fen/Phen: An epidemic foretold. Circulation 1999; 99: 156-161.
34. 34 Seiler KU, Wassermann O, Wensky H. On the role of serotonin in the pathogenesis of pulmonary hypertension induced by anorectic drugs; an experimental study in the isolated perfused rat lung, II. Fenfluramine, mazindol, mefenorex, phentermine and R 800. Clinical & Experimental Pharmacol Physiol 1976; 3: 323-330.
35. 35 Herve P, Launay J.M, Serobohaci ML, Brenot F, Simoneau G, Pettipretz P, Poubeau P, Cerrina J, Duroux P, Drouet L. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-254.
36. 36 Brink C, Cerrina C, Labat C et al. The effects of contractile agonists on isolated pulmonary arterial and venous muscle preparations derived from patients with primary pulmonary hypertension Am Rev Respir Dis 1988; 137/part 2: A106.
37. 37 Hosoda Y. Pathology of pulmonary hypertension: A human and experimental study. Pathol Intl 1994; 44: 241-267.
38. 38 Kanai Y, Hori S, Tanaka T, Yasuok M, Watanabe K, Aikaa N, Hosoda Y. Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats. Cardiovasc Res 1993; 27: 1619-1623.
39. 39 Reeve HL, Nelson DP, Archer SL, Weir KE. The effects of fluoxetine, phentermine, and venlafaxine on pulmonary artery pressure and electrophysiology. Am J Physiol 1999; 213-219.
40. 40 Khan MA, Herzog CA, Stpeter JV, Hartley GG, Madlonkay R, Dick CD, Asinger RW, Vessey JT. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. New Eng J Med 1998; 339: 713-718.
41. 41 Wee CC, Phillips RS, Aurigemma G, Erban S, Kriegel G, Riley M, Douglas PS. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Internal Med 1998; 129: 870-874.
42. 42 Gross SD, Leper NB, Daley WL, Buchbinder NA, Hicky A, Samuels BA. Dose and duration of appetite suppressant activity impacts incidence of valvular heart disease. Circulation 1998; 138.
43. 43 Gardin JM. An echocardiographic evaluation of patients exposed to anorexigens as compared to unmatched controls. Presentation at the 1988 meeting of the AHA, Dallas, TX.
44. 44 Shively BK. Echocardiographic diagnosis. Presentation at the 1998 AHA meeting Dallas, Texas.
45. 45 Maher TJ, Ulus IH, Wurtman RJ. Phentermine and other monoamine oxidase inhibitors may increase plasma serotonin when given with fenfluramines. Lancet 1999; 353: 38.
46. 46 Lundin, L. Carcinoid heart disease: A cardiologist's view-point. Acta Oncologica 1991; 30: 499-502.
47. 47 Redfield MM, Nicholson WJ, Edwards WD, Tajk, AJ Valve disease associated with ergot alkaloid use: Echocardiographic and pathologic correlations. Ann Intern Med, 1992; 117: 50-52.
48. 48 McCann U, Hatzidimitriou G, Ridenour A, Fischer C, Yuan J, Katz J, Ricaurte G. Dexfenfluramine and serotonin neurotoxicity: Further preclinical evidence that clinical caution is indicated. J Pharmacol Exptl Therapeut 1994; 269: 792-798.
49. 49 Baumann MH, Schuster CR, Rothman RB. Effects of phentermine and cocaine on fenfluramine-induced depletion of serotonin in mouse brain. Drug Alc Dep 1996; 41: 71-74.
50. 50 Halladay AK, Fisher H, Wagner GC. Interaction of phentermine plus fenfluramine: neurochemical and neurotoxic effects. Neurotoxicol 1998; 19: 177-183.
51. 51 Lew R, Weisenberg B, Vosmer G, Seiden LS. Combined phentermine/fenfluramine administration enhances depletion of serotonin from central terminal fields. Synapse 1997; 26: 36-45.
52. 52 McCann U, Jie Y, Ricaurte GA. Neurotoxic effects of (+/-)fenfluramine and phentermine, alone and in combination, on monoamine neurons in the mouse brain. Synapse 1998; 30: 239-246.
53. 53 Hunsinger RN, Kibbe AH, Wilson MC. The effect of previous d-amphetamine treatment on the disposition and lethality of fenfluramine in the rat. Toxicol Appl Pharmacol 1985; 79: 236-245.
54. 54 Weir EK, Reeve HL, Huang JM, Michelakis E, Nelson DP, Hampl V, Archer SL. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996; 94: 2216-2220.
55. 55 Reeve H, Archer SL, Weir EK. (1998) Dexfenfluramine releases intracellular Ca2 + in rat pulmonary artery smooth muscle cells. Circulation, 1790.
56. 56 Weir EK, Reeve HL, Johnson G, Michelakis ED, Nelson DP, Archer SL. A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension. Chest 1998; 114/3: Suppl, S200-S204.
57. 57 Moller-Nielsen I, Dubnick B. Pharmacology of chlorphentermine. In: Costa E. and Garattini (eds) Amphetamines and Related Compounds. Raven Press: New York, 1970, 63-73.
58. 58 Seller KU, Wasserman O. MAO-inhibitory properties of anorectic drugs. J Pharm Pharmacol 1973; 25: 576-578.
59. 59 Morita T, Mehendale HM. Effects of chlorphentermine and phentermine on the pulmonary disposition of 5-hydroxytryptamine in the rat in vivo. Am Rev Respir Dis 1983; 127: 747-750.
60. 60 Aulakh CS, Hill JL, Wozniak KM, Murphy DL. Fenfluramine-induced suppression of food intake and locomotor activity is differentially altered by the selective type A monoamine oxidase inhibitor clorgyline. Psychopharmacol 1988; 95: 313-317.
61. 61 Balcioglu A, Wurtman RJ. Effects of phentermine on striatal dopamine and serotonin release in conscious rats: in vivo microdialysis study. Intl J Obesity Rel Metabol Dis 1998; 22: 325-328.
62. 62 Shoaib M, Baumann MH, Rothman RB, Goldberg SR, Schindler CW. Behavioral and neurochemical characteristics of phentermine and fenfluramine admininistered separately and as a mixture in rats. Psychopharmacol 1996; 131: 296-306.
63. 63 Balcioglu A, Wurtman RJ. Effects of fenfluramine and phentermine (fen-phen) on dopamine and serotonin release in rat striatum: in vivo microdialysis study in conscious animals. Brain Res 1998; 813: 67-72.
64. 64 Fristrom S, Airaksinen MM, Halmekoski J. Release of platelet 5-hydroxytryptamine by some anorexic and other sympathomimetics and their acetyl derivatives. Acta Pharmacol Toxicologicol 1977; 41: 218-224.
65. 65 Redmon B, Raatz S, Bantle JP. Valvular heart disease associated with fenfluramine-phentermine. New Eng J Med 1997; 337/24: 1773-1774.